Other
Pd-1antibody
0
Pipeline Programs↗
9
Active Trials↗
2
Companies Involved↗
PD-1antibody is an early-stage landscape with 0 programs across 2 companies. The most active players are Taiho Oncology, Inc., HotSpot Therapeutics, Inc.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
25
clinical trials
Unknown status7 · 28%
Withdrawn7 · 28%
Recruiting4 · 16%
Active, not recruiting3 · 12%
Not yet recruiting2 · 8%
Completed1 · 4%
Other1 · 4%
Clinical Trials
Trial Activity
25 trials
The Immune Assessment of PD-1 Antibody Therapy in Tumor
Recruiting·—·N/A·NCT06693440·3,000 enrolled
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
Active, not recruiting·—·N/A·NCT06357806·45 enrolled
L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH
Not yet recruiting·—·Phase 3·NCT05315336·50 enrolled
Lenvatinib Plus PD-1 Antibody for Unresectable ICC
Suspended·—·Phase 2·NCT03779100·25 enrolled
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
Withdrawn·—·Phase 2·NCT03775707
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)